Loading...
•
Mar 31, 2020
RAPT Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020.
Key Takeaways
RAPT Therapeutics reported a net loss of $13.1 million on revenue of $0.9 million for the first quarter of 2020. The company's cash, cash equivalents and marketable securities totaled $138.2 million as of March 31, 2020.
Net loss for the first quarter of 2020 was $13.1 million, compared to $9.2 million for the first quarter of 2019.
Revenue for the first quarter of 2020 was $0.9 million related to collaboration with Hanmi Pharmaceutical LTD.
Research and development expenses for the first quarter of 2020 were $10.7 million, compared to $7.9 million for the same period in 2019.
As of March 31, 2020, cash, cash equivalents and marketable securities were $138.2 million.
Forward Guidance
The press release contains forward-looking statements about the impact of COVID-19 on the clinical development of FLX475 and RPT193 and the anticipated timing of clinical data.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...